Get the Stockscreener App
0.3019
2.01%
-0.0062
After Hours:
.30
-0.0019
-0.63%
Gri Bio Inc stock is traded at $0.3019, with a volume of 978.67K.
It is down -2.01% in the last 24 hours and down -85.34% over the past month.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
See More
Previous Close:
$0.3081
Open:
$0.2919
24h Volume:
978.67K
Relative Volume:
0.62
Market Cap:
$3.06M
Revenue:
-
Net Income/Loss:
$-8.26M
P/E Ratio:
-0.00563
EPS:
-53.609
Net Cash Flow:
$-12.17M
1W Performance:
+8.52%
1M Performance:
-85.34%
6M Performance:
-79.03%
1Y Performance:
-97.87%
1-Day Range:
$0.281
$0.3019
1-Week Range:
$0.2315
$0.3081
52-Week Range:
$0.2177
$14.45
Gri Bio Inc Stock (GRI) Company Profile
Name
Gri Bio Inc
Sector
Industry
Phone
(619) 400-1171
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA
Compare GRI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
0.3019 | 3.12M | 0 | -8.26M | -12.17M | -53.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | H.C. Wainwright | Buy |
Gri Bio Inc Stock (GRI) Latest News
What drives GRI Bio Inc stock priceEarnings Forecast Updates & High Yield Trading Growth - earlytimes.in
Decliners Report: Is GRI Bio Inc stock attractive for hedge funds2025 Bull vs Bear & Free Community Consensus Stock Picks - moha.gov.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
GRI Bio approves reverse stock split, stockholders vote in favor - MSN
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
GRI Bio Inc. (GRI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What technical signals suggest for GRI Bio Inc. stockEarnings Growth Report & Safe Entry Point Identification - Улправда
What insider trading reveals about GRI Bio Inc. stockLong Setup & Real-Time Buy Zone Alerts - Улправда
Why GRI Bio Inc. stock remains on buy listsWeekly Trade Analysis & Weekly Setup with High ROI Potential - Улправда
Why GRI Bio Inc. stock could be next big winnerJuly 2025 Intraday Action & Expert Approved Momentum Ideas - DonanımHaber
What sentiment indicators say about GRI Bio Inc. stockWeekly Market Outlook & Weekly Momentum Stock Picks - Улправда
Market Leaders: What Wall Street predicts for GRI Bio Inc. stock priceQuarterly Growth Report & Smart Investment Allocation Insights - Улправда
GRI Bio announces GRI-0621-IPF-02 trial met primary, secondary endpoints - MSN
GRI Bio Closes $8 Million Public Offering - The Globe and Mail
GRI Bio closes $8 million public offering of common stock and warrants - Investing.com Nigeria
GRI Bio closes $8 million public offering of common stock and warrants By Investing.com - Investing.com South Africa
GRI Bio (Nasdaq: GRI) details closing of offering, equity over $2.5M post-transaction - Stock Titan
GRI Bio Announces Closing of $8.0 Million Public Offering - GlobeNewswire
GRI Bio Launches $6.7 Million Public Offering - TipRanks
GRI Bio (NASDAQ: GRI) details $6.7M equity deal and runway into Q4 2026 - Stock Titan
GRI Bio prices $8 million public offering at $0.75 per share - Investing.com
GRI Bio announces pricing of $8M public offering - MSN
GRI Bio’s IPF drug shows positive Phase 2a results with improved lung function - Investing.com India
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
GRI Bio Announces Pricing of $8,000,000 Million Public Offering - The Manila Times
GRI Bio (NASDAQ: GRI) prices $8,000,000 offering of 10,666,667 shares at $0.75 - Stock Titan
What's Going On With GRI Bio Stock Thursday?GRI Bio (NASDAQ:GRI) - Benzinga
GRI Bio’s tazarotene achieves Phase IIa IPF success - Yahoo
GRI Bio Meets Key Goals In Phase 2 Trial Of GRI-0621 For Idiopathic Pulmonary Fibrosis - Nasdaq
GRI Bio announces positive Phase 2a trial results - MSN
GRI Bio Announces Positive Phase 2a Trial Results - TipRanks
GRI Bio, Inc. Announces Positive Phase 2a Trial Results for GRI-0621 - TradingView
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire
A new trading data show Milestone Pharmaceuticals Inc (MIST) is showing positive returns. - Setenews
GRI Bio (NASDAQ: GRI) updates Form S-1 with extensive warrant and contract exhibits - Stock Titan
Financial Contrast: CalciMedica (NASDAQ:CALC) and GRI Bio (NASDAQ:GRI) - Defense World
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.45% - Investing.com UK
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.45% - Investing.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
GRI Bio Reports Positive Phase 2a Trial Results - TipRanks
GRI Bio Increceives topline data from phase 2a trial for idiopathic pulmonary fibrosisSEC filing - marketscreener.com
GRI Bio Reports Positive Phase 2a Trial Results for IPF Treatment - TradingView
GRI Bio (NASDAQ: GRI) reports Phase 2a IPF topline results for GRI-0621 - Stock Titan
Ascendiant Capital Maintains GRI Bio (GRI) Buy Recommendation - Nasdaq
Ascendiant Capital Raises Price Target for GRI to $36.00 | GRI S - GuruFocus
Why GRI Bio Inc. stock is seen as undervaluedSell Signal & Weekly Return Optimization Alerts - Newser
JTC Team Companies to Present in Webull Corporate Connect Webinar Series: Biotech/MedTech on August 19-21, 2025 - The Herald-Mail
GRI Bio receives Nasdaq notice for non-compliance with equity listing rule - Investing.com Australia
GRI Bio (GRI) Stock Analysis Report | Financials & Insights - Benzinga
Stop Loss: What sentiment indicators say about GRI Bio Inc. stock2025 Retail Activity & Long-Term Growth Portfolio Plans - moha.gov.vn
Buy Signal: What insider trading reveals about GRI Bio Inc. stock2025 Technical Overview & Low Risk Profit Maximizing Plans - moha.gov.vn
Gri Bio Inc Stock (GRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):